Seattle-based KPI Therapeutics is looking to raise more than $25 million to undertake clinical development of its drugs.
The company, which is developing drugs to treat autoimmune conditions and chronic pain, kicked off its fundraising at an industry conference earlier this month, CEO Charles Magness said.
KPI is talking with institutional players and private equity groups, he said. It is considering funders ranging from venture capital firms to hedge funds, to the venture capital arms of pharmaceutical…Seattle-based KPI Therapeutics is looking to raise more than $25 million to undertake clinical development of its drugs.
The company, which is developing drugs to treat autoimmune conditions and chronic pain, kicked off its fundraising at an industry conference earlier this month, CEO Charles Magness said.
KPI is talking with institutional players and private equity groups, he said. It is considering funders ranging from venture capital firms to hedge funds, to the venture capital arms of pharmaceutical…